## Christina L Addison

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4067690/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models. British Journal of Cancer, 2022, , .	6.4	Ο
2	Focal Adhesion Kinase Inhibitors Prevent Osteoblast Mineralization in Part Due to Suppression of Akt-mediated stabilization of Osterix. Journal of Bone Oncology, 2022, , 100432.	2.4	2
3	Mapping vitamin B <sub>6</sub> metabolism by hydrazoCEST magnetic resonance imaging. Chemical Communications, 2021, 57, 10867-10870.	4.1	5
4	Targeting Intercellular Communication in the Bone Microenvironment to Prevent Disseminated Tumor Cell Escape from Dormancy and Bone Metastatic Tumor Growth. International Journal of Molecular Sciences, 2021, 22, 2911.	4.1	4
5	Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells. International Journal of Molecular Sciences, 2020, 21, 5788.	4.1	11
6	The plasma peptides of breast versus ovarian cancer. Clinical Proteomics, 2019, 16, 43.	2.1	16
7	Dual inhibition of Wnt and Yesâ€associated protein signaling retards the growth of tripleâ€negative breast cancer in both mesenchymal and epithelial states. Molecular Oncology, 2018, 12, 423-440.	4.6	54
8	The plasma peptides of ovarian cancer. Clinical Proteomics, 2018, 15, 41.	2.1	33
9	The plasma peptidome. Clinical Proteomics, 2018, 15, 39.	2.1	22
10	Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death and Disease, 2018, 9, 815.	6.3	34
11	A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. Lung Cancer, 2017, 104, 65-69.	2.0	19
12	MicroRNA-30b controls endothelial cell capillary morphogenesis through regulation of transforming growth factor beta 2. PLoS ONE, 2017, 12, e0185619.	2.5	17
13	Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0150567.	2.5	32
14	Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2016, 7, 771-785.	1.8	66
15	Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS). Journal of Bone Oncology, 2016, 5, 57-62.	2.4	9
16	Strategies for obtaining bone biopsy specimens from breast cancer patients – Past experience and future directions. Journal of Bone Oncology, 2016, 5, 180-184.	2.4	1
17	Issues Affecting the Loco-regional and Systemic Management of Patients with Invasive Lobular Carcinoma of the Breast. Breast Journal, 2016, 22, 45-53.	1.0	14
18	Both bulk and cancer stem cell subpopulations in tripleâ€negative breast cancer are susceptible to Wnt, <scp>HDAC</scp> , and <scp>ER</scp> α coinhibition. FEBS Letters, 2016, 590, 4606-4616.	2.8	28

Christina L Addison

#	Article	IF	CITATIONS
19	Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study. Journal of Bone Oncology, 2015, 4, 47-53.	2.4	7
20	Treatment choices for patients with invasive lobular breast cancer: a doctor survey. Journal of Evaluation in Clinical Practice, 2015, 21, 740-748.	1.8	12
21	Evaluating the Feasibility of Performing Window of Opportunity Trials in Breast Cancer. International Journal of Surgical Oncology, 2015, 2015, 1-9.	0.6	10
22	VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell, 2015, 28, 210-224.	16.8	77
23	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nature Medicine, 2015, 21, 530-536.	30.7	118
24	Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. Cancer Research, 2015, 75, 3479-3491.	0.9	375
25	Invasive Pleomorphic Lobular Carcinoma of the Breast: Pathologic, Clinical, and Therapeutic Considerations. Clinical Breast Cancer, 2015, 15, 421-425.	2.4	33
26	Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24. Clinical Lung Cancer, 2015, 16, e189-e201.	2.6	6
27	Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial. Lung Cancer, 2015, 90, 288-295.	2.0	6
28	Pharmacotherapy of bone metastases in breast cancer patients – an update. Expert Opinion on Pharmacotherapy, 2014, 15, 1109-1118.	1.8	8
29	Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. SpringerPlus, 2014, 3, 577.	1.2	18
30	A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events. Breast Cancer Research and Treatment, 2014, 144, 615-624.	2.5	25
31	Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting. Journal of Bone Oncology, 2014, 3, 1-4.	2.4	5
32	Essential role for the SLK protein kinase in embryogenesis and placental tissue development. Developmental Dynamics, 2014, 243, 640-651.	1.8	13
33	De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists. Journal of Bone Oncology, 2013, 2, 77-83.	2.4	24
34	Does estrogen play a role in response to adjuvant bone-targeted therapies?. Journal of Bone Oncology, 2013, 2, 167-173.	2.4	6
35	A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer. Journal of Bone Oncology, 2013, 2, 123-131.	2.4	21
36	Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey. Journal of Bone Oncology, 2013, 2, 105-109.	2.4	18

#	Article	IF	CITATIONS
37	Incidence and consequences of bone metastases in lung cancer patients. Journal of Bone Oncology, 2013, 2, 22-29.	2.4	78
38	Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers. Journal of Bone Oncology, 2013, 2, 154-157.	2.4	15
39	Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists. Journal of Bone Oncology, 2013, 2, 38-46.	2.4	14
40	miR-105 Inhibits Prostate Tumour Growth by Suppressing CDK6 Levels. PLoS ONE, 2013, 8, e70515.	2.5	42
41	Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases. Journal of Clinical Medicine, 2013, 2, 67-88.	2.4	7
42	Skeletal-related events (SRE) and bone-targeted agents for metastatic prostate cancer: Are we changing outcomes?. Journal of Clinical Oncology, 2013, 31, e16074-e16074.	1.6	1
43	Breast cancer biomarker discordance between primary and sites of metastasis: A systematic review Journal of Clinical Oncology, 2013, 31, e11574-e11574.	1.6	0
44	Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial Journal of Clinical Oncology, 2013, 31, 8048-8048.	1.6	1
45	β1 integrin. Cell Adhesion and Migration, 2012, 6, 71-77.	2.7	53
46	Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?. Journal of Bone Oncology, 2012, 1, 12-17.	2.4	12
47	β1 integrin is required for anchorage-independent growth and invasion of tumor cells in a context dependent manner. Cancer Letters, 2012, 316, 157-167.	7.2	16
48	RhoB controls endothelial cell morphogenesis in part via negative regulation of RhoA. Vascular Cell, 2012, 4, 1.	0.2	40
49	Adjuvant bisphosphonate treatment for breast cancer: Why did something so elegant become so complicated?. Breast Cancer Research and Treatment, 2012, 134, 453-457.	2.5	10
50	Serum activinA and TGF-β as biomarkers of breast cancer bone metastasis behavior Journal of Clinical Oncology, 2012, 30, 10620-10620.	1.6	0
51	Focal adhesion kinase inhibitors are potent antiâ€angiogenic agents. Molecular Oncology, 2011, 5, 517-526.	4.6	74
52	Plasma Transforming Growth Factor α and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21. Journal of Clinical Oncology, 2010, 28, 5247-5256.	1.6	51
53	Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells. Cancer Letters, 2007, 252, 195-207.	7.2	16
54	The inhibitory effects of endostatin on endothelial cells are modulated by extracellular matrix. Experimental Cell Research, 2006, 312, 2476-2489.	2.6	20

#	Article	IF	CITATIONS
55	Modulation of response to tumor therapies by the extracellular matrix. Future Oncology, 2006, 2, 417-429.	2.4	10
56	The response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent. BMC Cell Biology, 2005, 6, 38.	3.0	27